Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...
GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...
The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...
MEMS, wearable/implantable electronics and bio-tissue therapeutics, the pursuit of piezoelectric biomaterials has become a ...
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space ...
The company ended the quarter with $192 million in cash and equivalents, enough to fund operations past 2027. 2seventy Bio ...
The clinical stage biopharmaceutical company is developing inhaled drug delivery devices. Transpire Bio expands headquarters ...
Binance Labs has invested in BIO Protocol, a pioneering protocol transforming the way early-stage scientific research is ...
The European Commission is asking biopharma and manufacturing companies about their reaction to Novo ...
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, ...
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
Zacks.com on MSN7h
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue EstimatesBluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago. These figures are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback